Hebei Kexing Pharmaceutical Co., Ltd.
Model No.: 5% 100ml
Varieties: General Disease Prevention Medicine
Component: Chemical Synthetic Drugs
Type: The First Class
Pharmacodynamic Influential Factors: Repeated Medication
Storage Method: Moisture Proof
Packaging: 5% 100ml/bottle/box, 80bottles/carton
Productivity: 20000 bottles per day
Place of Origin: Hebei, China (Mainland)
Supply Ability: 20000 bottles per day
Certificate: GMP ISO
HS Code: 3004909099
Flunixin Meglumine Injection 5%
Flunixin meglumine Injection 5% is a relatively potent non-narcotic, non-steroidal analgesic with anti-inflammatory and anti-pyretic properties. In the horse, Flunixin Injection is indicated for the alleviation of inflammation and pain associated with musculo-skeletal disorders especially in acute and chronic stages and for the alleviation of visceral pain associated with colic. In cattle,Flunixin Meglumine Injection is indicated for the control of acute inflammation associated with respiratory disease.Flunixin Injection can not administer to pregnant animals.
Dosage Administration:Flunixin Injection is indicated for intravenous administration to cattle and horses. HORSES: For use in equine colic, the recommended dose rate is 1.1 mg flunixin/kg bodyweight equivalent to 1 ml per 45 kg bodyweight by intravenous injection. Treatment may be repeated once or twice if colic recurs. For use in musculo-skeletal disorders, the recommended dose rate is 1.1 mg flunixin/kg bodyweight, equivalent to 1 ml per 45 kg bodyweight injected intravenously once daily for up to 5 days according to clinical response. CATTLE: The recommended dose rate is 2.2 mg flunixin/kg bodyweight equivalent to 2 ml per 45 kg bodyweight injected intravenously and repeated as necessary at 24 hour intervals for up to 3 consecutive days.
Do not administer to pregnant animals. Monitor drug compatibility closely where adjunctive therapy is required. Avoid intra-arterial injection. It is preferable that NSAIDs, which inhibit prostaglandin synthesis, are not administered to animals undergoing general anaesthesia until fully recovered. Horses intended for racing and competition should be treated according to local requirements and appropriate precautions must be taken to ensure compliance with the competition regulations. In case of doubt it is advisable to test the urine. The cause of the underlying inflammatory condition or colic should be determined and treated with appropriate concomitant therapy.Use is contra-indicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastrointestinal ulceration or bleeding, where there is evidence of a blood dyscrasia or hypersensitivity to the product. Do not administer other non-steroidal anti-inflammatory drugs (NSAIDs) concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs which can lead to toxic effects. Use in any animal less than 6 weeks of age or in aged animals may involve an additional risk. If such use cannot be avoided animals may require a reduced dosage and careful clinical management. Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity. Concurrent administration of potentially nephrotoxic drugs should be avoided. In case of spillage onto skin wash immediately with water. To avoid possible sensitisation reactions, avoid contact with the skin. Gloves should be worn during application. The product may cause reactions in sensitive individuals. If you have known hypersensitivity for non-steriodal anti-inflammatory products do not handle the product. Reactions may be serious.
Cattle may be slaughtered for human consumption only after 14 days from the last treatment. Horses may be slaughtered for human consumption only after 28 days from the last treatment. Milk for human consumption must not be taken during treatment. Milk for human consumption may only be taken from treated cows after 2 days from the last treatment.
Do not store above 25℃. Protect from light. Store out of reach of children. Avoid introduction of contamination. Following withdrawal of the first dose, use the product within 28 days. Discard unused product. At the first time of use, insert the date to discard the product on the label.
Copyright © 2019 Hebei Kexing Pharmaceutical Co., Ltd. All rights reserved.